GnRH Agonists and Antagonists in Endometriosis and Adenomyosis Therapy

Endometriosis and adenomyosis are estrogen dependent disorders and hence, one of the major pillars in their medical management has been to suppress circulating estrogen levels. Given that the primary source of premenopausal endogenous estrogen is estradiol production from the ovaries, the principal mechanism for estrogen suppression has been through inhibition of the hypothalamic-pituitary-ovarian (HPO) axis with GnRH agonists. Over the last 15–20 years, GnRH antagonists have also been developed for this purpose. This chapter will provide an overview of the use of GnRH agonists and antagonists for the treatment of endometriosis and adenomyosis. Access this chapter We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact support so we can address the problem. Similar content being viewed by others Change history 10 September 2022 Correction to:

Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631–3. https://doi.org/10.1126/science.100883. Schally AV, Arimura A, Kastin AJ, et al. Gonadotropinreleasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. 1971. https://doi.org/10.1126/science.173.4001.1036. Burgus R, et al. Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF). Proceedings of the National Academy of Sciences. 1972;69(1):278–82. Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: understanding advantages and limitations. J Human Reproduct Sci. 2014;7(3):170–174. Medknow Publications. https://doi.org/10.4103/0974-1208.142476 Agarwal SK. Differential effects of GnRH agonist therapies: implications regarding the Estrogen Threshold Hypothesis. In: Lemay A, Maheux R, editors. Understanding and managing endometriosis: advances in research and practice (proceedings of the VIth world congress on endometriosis). Parthenon Publishing; 1999. p. 199–204. Practice Committee of the American Society for Reproductive Medicine, T. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101(4):927–35. https://doi.org/10.1016/j.fertnstert.2014.02.012. Nelson JR, Corson SL. Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report. Fertil Steril. 1993;59(2):441–3. https://doi.org/10.1016/s0015-0282(16)55704-5. Pontis A, et al. Adenomyosis: a systematic review of medical treatment. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2016;32(9):696–700. https://doi.org/10.1080/09513590.2016.1197200. Surrey ES, Soliman AM, Palac HL, Agarwal SK. Impact of Elagolix on workplace and household productivity among women with moderate to severe pain associated with endometriosis: a pooled analysis of two phase III trials. Patient. 2019;12(6):651–60. https://doi.org/10.1007/s40271-019-00394-7. Agarwal SK et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019;220(4):354.e1–354.e12. https://doi.org/10.1016/j.ajog.2018.12.039. Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017;108(1):125–36. https://doi.org/10.1016/j.fertnstert.2017.05.004. Ishihara H, Kitawaki J, Kado N, Koshiba H, Fushiki S, Honjo H. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. Fertil Steril. 2003;79(Suppl 1):735–42. https://doi.org/10.1016/s0015-0282(02)04813-6. PMID: 12620485 Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynecol Obstet. 2012;117(3):228–33. https://doi.org/10.1016/j.ijgo.2012.01.009. Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril. 1993;59(3):511–5. https://doi.org/10.1016/S0015-0282(16)55791-4. Agarwal SK. Comparative effects of GnRH agonist therapy. Review of clinical studies and their implications. J Reprod Med. 1998;43(3 Suppl):293–8. Surrey ES, Gambone JC, Lu JK, Judd HL. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril. 1990;53(4):620–6. PMID: 2108056 Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab. 1992;75(2):558–63. https://doi.org/10.1210/jcem.75.2.1386374. PMID: 1386374 Makarainen L, Ronnberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril. 1996;65(1):29–34. https://doi.org/10.1016/S0015-0282(16)58023-6. Moghissi KS, Schlaff WD, Olive DL, Skinner MA, Yin H. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril. 1998;69(6):1056–62. https://doi.org/10.1016/S0015-0282(98)00086-7. Kiilholma P, Tuimala R, Kivinen S, Korhonen M, Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril. 1995;64(5):903–8. https://doi.org/10.1016/S0015-0282(16)57900-X. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12- month study. Obstet Gynecol. 1998;91(1):16–24. https://doi.org/10.1016/S0029-7844(97)00620-0. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in Hypogonadal men. J Clin Endocrinol Metabol. 1997;82(8):2386–90. https://doi.org/10.1210/jcem.82.8.4163. Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril. 1997;67(1):40–5. https://doi.org/10.1016/S0015-0282(97)81853-5. Agarwal SK, Daniels A, Drosman SR, Udoff L, Foster WG, Pike MC, Spicer DV, Daniels JR. Treatment of endometriosis with the GnRHa deslorelin and add-back estradiol and supplementary testosterone. Biomed Res Int. 2015;2015 https://doi.org/10.1155/2015/934164. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2):740–5. https://doi.org/10.1016/0002-9378(92)91706-G. Agarwal SK, Hamrang C, Henzl MR, Judd HL. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. J Reprod Med. 1997;42(7):413–23. PMID: 9252932 Tahara M, Matsuoka T, Yokoi T, Tasaka K, Kurachi H, Murata Y. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy). Fertil Steril. 2000;73(4):799–804. https://doi.org/10.1016/s0015-0282(99)00636-6. PMID: 10731543 Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Obstet Gynecol. 1999;93(1):51–8. https://doi.org/10.1016/S0029-7844(98)00341-X. Selçuk I, Bozdaǧ G. Recurrence of endometriosis; risk factors, mechanisms and biomarkers; review of the literature. J Turkish German Gynecol Assoc. 2013;14(2):98–103. AVES. https://doi.org/10.5152/jtgga.2013.52385 Papari E, et al. Identification of candidate microRNA markers of endometriosis with the use of next-generation sequencing and quantitative real-time polymerase chain reaction. Fertil Steril. 2020;113(6):1232–41. https://doi.org/10.1016/j.fertnstert.2020.01.026. Vanhie A, et al. Peritoneal fluid exosomes as potential biomarkers for endometriosis: mind and bridge the gap between innovation and validation/development into benefit for patients. Fertil Steril. 2020;113(2):326–7. https://doi.org/10.1016/j.fertnstert.2019.12.031. Nisenblat V, et al. Imaging modalities for the non-invasive diagnosis of endometriosis. The Cochrane database of systematic reviews. 2016;2(2):CD009591. https://doi.org/10.1002/14651858.CD009591.pub2. Cosar E, et al. Serum microRNAs as diagnostic markers of endometriosis: a comprehensive array-based analysis. Fertil Steril vol. 2016;106(2):402–9. https://doi.org/10.1016/j.fertnstert.2016.04.013. Hornstein MD, Hemmings R, Yuzpe AA, Leroy Heinrichs W. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steriliw. 1997;68:Issue 6. Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. BJOG Int J Obstetr Gynaecol. 1999;106(7):672–7. https://doi.org/10.1111/j.1471-0528.1999.tb08366.x. Vercellini P, Barbara G, Abbiati A, Somigliana E, Viganò P, Fedele L. Repetitive surgery for recurrent symptomatic endometriosis: what to do? Eur J Obstet Gynecol Reprod Biol. n.d.; https://doi.org/10.1016/j.ejogrb.2009.05.007. Falcone T, Shakiba K, Bena JF, McGill KM, Minger J. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol. 2008;111(6):1285–92. https://doi.org/10.1097/AOG.0b013e3181758ec6. Bar-Shavit Y, Jaillet L, Chauvet P, Canis M, Bourdel N. Use of indocyanine green in endometriosis surgery. Fertil Steril. 2018;109(6):1136–7. https://doi.org/10.1016/j.fertnstert.2018.02.113. Leonardi M, Martin E, Reid S, Blanchette G, Condous G. Deep endometriosis transvaginal ultrasound in the workup of patients with signs and symptoms of endometriosis: a cost analysis. BJOG. 2019;126(12):1499–506. https://doi.org/10.1111/1471-0528.15917. Epub 2019 Sep 18 Leonardi M, Robledo KP, Goldstein SR, Benacerraf BR, Condous G. International survey finds majority of gynecologists are not aware of and do not utilize ultrasound techniques to diagnose and map endometriosis. Ultrasound Obstet Gynecol. 2020;56(3):324–8. https://doi.org/10.1002/uog.21996. Heber D, Dodson R, Swerdloff RS, Channabasavaiah K, Stewart JM. Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action. Science. 1982;216(4544):420–1. https://doi.org/10.1126/science.6280278. Miller JD. Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol. 2000;182(6):1483–8. https://doi.org/10.1067/mob.2000.106846. Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS. Discovery of sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6- [trifluoromethyl]-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl] -1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–85. https://doi.org/10.1021/jm8006454. Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by Elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102:1683–91. https://doi.org/10.1210/jc.2016-3845. Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, et al. Treatment of endometriosis-associated pain with Elagolix, an Oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. https://doi.org/10.1056/NEJMoa1700089. Surrey E, et al. Longt-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147–60. https://doi.org/10.1097/AOG.0000000000002675. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG About this chapter Cite this chapter Anglin, H.P., Foster, W.G., Agarwal, S.K. (2022). GnRH Agonists and Antagonists in Endometriosis and Adenomyosis Therapy. In: Oral, E. (eds) Endometriosis and Adenomyosis. Springer, Cham. https://doi.org/10.1007/978-3-030-97236-3_43 Download citation DOI: https://doi.org/10.1007/978-3-030-97236-3_43 Published: Publisher Name: Springer, Cham Print ISBN: 978-3-030-97235-6 Online ISBN: 978-3-030-97236-3 eBook Packages: MedicineMedicine (R0)